Barclays analyst Balaji Prasad says Amneal Pharmaceuticals’ Complete Response Letter for IPX203 comes as a surprise. However, the firm views positively that no efficacy or manufacturing issues were flagged. Additional pharmacokinetics data will be required to achieve approval, ultimately delaying launch until at least the first half of 2024, the analyst tells investors in a research note. The firm keeps an Overweight rating on the shares with a $4 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMRX: